miR-2110 Affects the Biological Behaviors of Lung Adenocarcinoma by Regulating CDT1

MI Yuan, LI Xuzhe, WANG Cong, LIN Chenxi, ZHAO Zhichao, YAN Xiaofe, SHI Ping, WANG Lei

Abstract

To investigate the effect of miR-2110 on the biological behaviors, such as cell proliferation, apoptosis, and metastasis, of lung adenocarcinoma (LUAD) cells by means of cell and animal experiments.

Methods 

Bioinformatics websites, including ENCORI, TargetScan, miRTarBase, and Tarbase, were used to analyze the changes in the expression of miR-2110 in LUAD samples and to predict miR-2110 target. LUAD tissue samples and cells were collected and the changes in the expression of miR-2110 were verified through PCR technology. CCK-8 assay, clonogenic assay, Transwell assay, and flow cytometry were conducted to analyze alterations in the functions of LUAD cells. In addition, 10 BALB/c female nude mice aged 6 to 8 weeks were randomly divided into 2 groups, and the effect of miR-2110 on LUAD was investigated by in vivo experiments.

Results 

miR-2110 was significantly decreased in LUAD tissues and cells compared with the normal lung tissues. miR-2110 overexpression inhibited the proliferation and metastasis of LUAD cells and promoted the apoptosis of tumor cells (P<0.05). Bioinformatics prediction and dual luciferase reporter gene assay results confirmed that miR-2110 could target and bind to CDT1. In addition, overexpression of CDT1 gene reversed the proliferation, metastasis, and apoptosis of miR-2110 compared with the miR-2110 overexpression group (P<0.05). Nude mice in vivo experiments showed that miR-2110 overexpression significantly decreased the expression of Ki67, a tumor proliferation index, and vimentin and MMP9, two metastasis indices, compared with the control group.

Conclusion 

miR-2110 can inhibit proliferation and metastasis of LUAD by targeting CDT1, providing a new rationale for the treatment of LUAD.

 

Keywords: Adenocarcinoma of lung, miR-2110, CDT1, Tumor proliferation

 

Full Text:

PDF


References


HUIHUI L, ZEXIN C, NING C, et al. Applications of lung cancer organoids in precision medicine: from bench to bedside. Cell Commun Signal, 2023, 21(1): 350. doi: 10.1186/s12964-023-01332-9.

MAHMOOD Y, HABIB J, SOMAYEH H, et al. Cost of lung cancer: a systematic review. Value Health Reg Issues, 2022, 33: 17–26. doi: 10.1016/j.vhri.2022.07.007.

ROSAMARIA P, DANIELA P, ROSANNA L, et al. KRAS-driven lung adenocarcinoma and b cell infiltration: novel insights for immunotherapy. Cancers (Basel), 2019, 11(8): 1145. doi: 10.3390/cancers11081145.

SHAN J, AN Y, BUES M, et al. Robust optimization in IMPT using quadratic objective functions to account for the minimum MU constraint. Med Phys, 2018, 45(1): doi: 10.1002/mp.12677.

JIANG X, LI Y, ZHANG N, et al. RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma. Cell Biosci, 2021, 11(1): 74. doi: 10.1186/s13578-021-00586-5.

NAKANISHI T, YONESHIMA Y, OKAMURA K, et al. MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma. Cancer Sci, 2023, 114(10): doi: 10.1111/cas.15921.

ZHANG L P, BAI J, HU Y Q, et al. MiR-204 inhibits invasion and metastasis of breast cancer cells by targeted regulation of HNRNPA2B1. J South Med Univ, 2020, 40(6): doi: 10.12122/j.issn.1673-4254. 2020.06.15.

SON S M, YUN J, KIM D W, et al. MicroRNA 29a therapy for CEACAM6-expressing lung adenocarcinoma. BMC Cancer, 2023, 23(1): 843. doi: 10.1186/s12885-023-11352-w.

ZHU J Y, PFUHL T, MOTSCH N, et al. Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J Virol, 2009, 83(7): 3333-3341. doi: 10.1128/JVI.01689-08.

ZHANG X, LI F, ZHOU Y, et al. Long noncoding RNA AFAP1-AS1 promotes tumor progression and invasion by regulating the miR-2110/Sp1 axis in triple-negative breast cancer. Cell Death Dis, 2021, 12(7): 627. doi: 10.1038/s41419-021-03917-z.

ZHAO Z, PARTRIDGE V, SOUSARES M, et al. microRNA-2110 functions as an onco-suppressor in neuroblastoma by directly targeting Tsukushi. PLoS One, 2018, 13(12): e0208777. doi: 10.1371/journal.pone. 0208777.

FERRACIN M, LUPINI L, SALAMON I, et al. Absolute quantification of cell-free microRNAs in cancer patients. Oncotarget, 2015, 6(16): 14545–14555. doi: 10.18632/oncotarget.3859.

ZHANG B, WANG D, WANG Y, et al. miRNA-338-3p inhibits the migration, invasion and proliferation of human lung adenocarcinoma cells by targeting MAP3K2. Aging (Albany NY), 2022, 14(15): 6094–6110. doi: 10.18632/aging.204198.

HE B, ZHAO Z, CAI Q, et al. miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci, 2020, 16(14): 2628–2647. doi: 10.7150/ijbs.47203.

TANIGAWA K, TOMIOKA Y, MISONO S, et al. Minichromosome maintenance proteins in lung adenocarcinoma: clinical significance and therapeutic targets. FEBS Open Bio, 2023, 13(9): 1737–1755. doi: 10.1002/ 2211-5463.13681.

MAJIDPOOR J, MORTEZAEE K. Steps in metastasis: an updated review. Med Oncol, 2021, 38(1): 3. doi: 10.1007/s12032-020-01447-w.

KIM J, YOU H J, YOUN C. SCARA3 inhibits cell proliferation and EMT through AKT signaling pathway in lung cancer. BMC Cancer, 2022, 22(1): 552. doi: 10.1186/s12885-022-09631-z.

MI Y, LIANG Y X, WANG C, et al. Targeting CDT1 inhibit tumor growth and its mechanism in lung adenocarcinoma. Acta Univer Med Anhui, 2024, 59(2): 260–266. doi: 10.19405/ j.cnki. issn1000-1492.2024.02. 013.

SHI H X, HUANG S W, LUO W J, et al. Elevated expression of CDT1 in childhood acute lymphoblastic leukemia promotes cell proliferation, invasion and migration through activation of EMT. J Biol Regul Homeost Agents, 2021, 35 (Special Issue on Internal Medicine n.1). doi: 10.23812/ 21-SI1-6.

FANG S, PENG L, ZHANG M, et al. MiR-2110 induced by chemically synthesized cinobufagin functions as a tumor-metastatic suppressor via targeting FGFR1 to reduce PTEN ubiquitination degradation in nasopharyngeal carcinoma. Environ Toxicol, 2024, 39(6): 3548–3562. doi: 10.1002/tox.24197.

HAN Y H, MA D Y, LEE S J, et al. Bioinformatics analysis of novel targets for treating cervical cancer by immunotherapy based on immune escape. Cancer Genomics Proteomics, 2023, 20(4): 383–397. doi: 10.21873/cgp. 20390.


Refbacks

  • There are currently no refbacks.